MA37693A1 - Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application - Google Patents
Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et applicationInfo
- Publication number
- MA37693A1 MA37693A1 MA37693A MA37693A MA37693A1 MA 37693 A1 MA37693 A1 MA 37693A1 MA 37693 A MA37693 A MA 37693A MA 37693 A MA37693 A MA 37693A MA 37693 A1 MA37693 A1 MA 37693A1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- improved
- powderiness
- manufacture
- application
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
- A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
- A61J3/074—Filling capsules; Related operations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention se rapporte au domaine de la pharmaceutique et notamment des compositions pharmaceutiques solides comprenant du 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol ou un sel pharmaceutiquement acceptable de celui-ci, une substance de glissement et une matière de charge ; l'invention concerne également des procédé de production de la composition pharmaceutique, des agents médicamenteux de suppression du système immunitaire et de traitement de la sclérose diffuse. Le 2-amino-2-[2-(4-octylphényl)éthyl]propane-1,3-diol consiste en un immuno-modulateur qui entraîne une redistribution des lymphocytes du flux sanguin dans les tissus lymphatiques secondaires, entraînant ainsi une immunosuppression. L'invention assure une répartition uniforme du composant actif dans la composition solide, une grande stabilité et une meilleure pulvérulence de la composition pharmaceutique. Grâce à cette meilleure pulvérulence, la composition de la présente invention peut être utilisée dans un équipement automatique
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2012129101/15A RU2496486C1 (ru) | 2012-07-11 | 2012-07-11 | Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение |
PCT/RU2013/000572 WO2014011083A2 (fr) | 2012-07-11 | 2013-07-05 | Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application |
Publications (2)
Publication Number | Publication Date |
---|---|
MA37693A1 true MA37693A1 (fr) | 2016-06-30 |
MA37693B1 MA37693B1 (fr) | 2017-01-31 |
Family
ID=49446598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37693A MA37693B1 (fr) | 2012-07-11 | 2014-12-24 | Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application |
Country Status (22)
Country | Link |
---|---|
US (1) | US9370576B2 (fr) |
EP (1) | EP2873416B1 (fr) |
JP (1) | JP6093015B2 (fr) |
KR (1) | KR20150036228A (fr) |
CN (1) | CN104487063B (fr) |
AP (1) | AP2014008171A0 (fr) |
BR (1) | BR112015000544A2 (fr) |
CL (1) | CL2015000052A1 (fr) |
CO (1) | CO7310521A2 (fr) |
EA (1) | EA027712B1 (fr) |
GE (1) | GEP201606571B (fr) |
IL (1) | IL236562A0 (fr) |
IN (1) | IN2015DN00130A (fr) |
MA (1) | MA37693B1 (fr) |
MX (1) | MX2015000467A (fr) |
PE (1) | PE20150632A1 (fr) |
RU (1) | RU2496486C1 (fr) |
SG (1) | SG11201500178QA (fr) |
TN (1) | TN2015000006A1 (fr) |
UA (1) | UA113216C2 (fr) |
WO (1) | WO2014011083A2 (fr) |
ZA (1) | ZA201409481B (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110398A1 (fr) | 2013-01-10 | 2014-07-17 | Edh Us Llc | Mesure de vitesse de rotation de balle |
RU2611415C1 (ru) * | 2015-11-17 | 2017-02-21 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты) |
WO2020005189A2 (fr) * | 2018-06-27 | 2020-01-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Compositions pharmaceutiques solides d'administration par voie orale comprenant du tériflunomide |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122011100012I1 (de) | 1992-10-21 | 2011-10-20 | Mitsubishi Tanabe Pharma Corp | 2-Amino-1, 3-propandiolverbindung und immunosuppressium. |
SK282225B6 (sk) | 1995-12-28 | 2001-12-03 | Welfide Corporation | Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku |
US6476004B1 (en) | 1996-07-18 | 2002-11-05 | Mitsubishi Pharma Corporation | Pharmaceutical composition |
GB9624038D0 (en) | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
JPH1180026A (ja) | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
JP2002316985A (ja) | 2001-04-20 | 2002-10-31 | Sankyo Co Ltd | ベンゾチオフェン誘導体 |
RU2358717C2 (ru) | 2002-05-16 | 2009-06-20 | Новартис Аг | Применение средств, связывающих edg-рецептор, в лечении ракового заболевания |
PE20150676A1 (es) * | 2003-04-08 | 2015-05-17 | Novartis Ag | Composicion farmaceutica que contiene un agonista del receptor s1p y un alcohol de azucar |
CA2539033C (fr) * | 2003-09-12 | 2013-03-05 | Neuronova Ab | Traitement d'une maladie ou d'une lesion du systeme nerveux au moyen de fty720 |
US20080096972A1 (en) | 2004-07-30 | 2008-04-24 | Thitiwan Buranachokpaisan | Compound formulations of 2-amino-1, 3-propanediol compounds |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
MXPA05008573A (es) | 2005-08-12 | 2007-02-12 | Leopoldo Espinosa Abdala | Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia. |
EP1923058A1 (fr) * | 2006-09-26 | 2008-05-21 | Novartis AG | Composition pharmaceutique enrobée comprenant un agoniste ou un modulateur de S1P |
KR102044064B1 (ko) * | 2006-09-26 | 2019-11-12 | 노파르티스 아게 | S1p 조정제를 포함하는 제약 조성물 |
KR101600098B1 (ko) * | 2007-10-12 | 2016-03-04 | 노파르티스 아게 | 스핑고신 1 포스페이트 (s1p) 수용체 조절제를 포함하는 조성물 |
CA2797042A1 (fr) * | 2010-04-22 | 2011-10-27 | Ratiopharm Gmbh | Fingolimod sous la forme de solution solide |
CA2797551A1 (fr) * | 2010-04-22 | 2011-10-27 | Ratiopharm Gmbh | Fingolimod granule fondu |
-
2012
- 2012-07-11 RU RU2012129101/15A patent/RU2496486C1/ru active
-
2013
- 2013-05-07 UA UAA201500892A patent/UA113216C2/uk unknown
- 2013-07-05 AP AP2014008171A patent/AP2014008171A0/xx unknown
- 2013-07-05 KR KR1020157002215A patent/KR20150036228A/ko not_active Application Discontinuation
- 2013-07-05 JP JP2015521577A patent/JP6093015B2/ja not_active Expired - Fee Related
- 2013-07-05 US US14/410,584 patent/US9370576B2/en not_active Expired - Fee Related
- 2013-07-05 GE GEAP201313729A patent/GEP201606571B/en unknown
- 2013-07-05 WO PCT/RU2013/000572 patent/WO2014011083A2/fr active Application Filing
- 2013-07-05 EP EP13817392.7A patent/EP2873416B1/fr not_active Not-in-force
- 2013-07-05 EA EA201500096A patent/EA027712B1/ru not_active IP Right Cessation
- 2013-07-05 PE PE2015000009A patent/PE20150632A1/es not_active Application Discontinuation
- 2013-07-05 MX MX2015000467A patent/MX2015000467A/es unknown
- 2013-07-05 CN CN201380036592.6A patent/CN104487063B/zh not_active Expired - Fee Related
- 2013-07-05 SG SG11201500178QA patent/SG11201500178QA/en unknown
- 2013-07-05 BR BR112015000544A patent/BR112015000544A2/pt active Search and Examination
-
2014
- 2014-12-22 ZA ZA2014/09481A patent/ZA201409481B/en unknown
- 2014-12-24 MA MA37693A patent/MA37693B1/fr unknown
-
2015
- 2015-01-01 IL IL236562A patent/IL236562A0/en unknown
- 2015-01-06 IN IN130DEN2015 patent/IN2015DN00130A/en unknown
- 2015-01-07 TN TNP2015000006A patent/TN2015000006A1/fr unknown
- 2015-01-08 CL CL2015000052A patent/CL2015000052A1/es unknown
- 2015-01-08 CO CO15003855A patent/CO7310521A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
EA201500096A1 (ru) | 2015-05-29 |
BR112015000544A2 (pt) | 2017-10-24 |
EA027712B1 (ru) | 2017-08-31 |
US20150335754A1 (en) | 2015-11-26 |
MX2015000467A (es) | 2015-06-05 |
TN2015000006A1 (en) | 2016-06-29 |
JP2015522068A (ja) | 2015-08-03 |
EP2873416B1 (fr) | 2017-04-26 |
WO2014011083A2 (fr) | 2014-01-16 |
GEP201606571B (en) | 2016-11-10 |
ZA201409481B (en) | 2016-02-24 |
KR20150036228A (ko) | 2015-04-07 |
CN104487063B (zh) | 2017-05-10 |
US9370576B2 (en) | 2016-06-21 |
IL236562A0 (en) | 2015-02-26 |
MA37693B1 (fr) | 2017-01-31 |
PE20150632A1 (es) | 2015-05-20 |
SG11201500178QA (en) | 2015-03-30 |
JP6093015B2 (ja) | 2017-03-08 |
AP2014008171A0 (en) | 2014-12-31 |
CL2015000052A1 (es) | 2015-09-04 |
EP2873416A4 (fr) | 2016-03-16 |
CN104487063A (zh) | 2015-04-01 |
WO2014011083A3 (fr) | 2014-03-06 |
IN2015DN00130A (fr) | 2015-05-29 |
EP2873416A2 (fr) | 2015-05-20 |
RU2496486C1 (ru) | 2013-10-27 |
CO7310521A2 (es) | 2015-06-30 |
UA113216C2 (xx) | 2016-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006421A (es) | Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17). | |
NZ704011A (en) | Abuse deterrent pharmaceutical compositions for controlled release | |
CY1124878T1 (el) | Διασπειρομενη στο στομα δοσολογικη μοναδα η οποια περιεχει ενα συστατικο οιστετρολης | |
MY168791A (en) | Carbamate compounds and of making and using same | |
MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
MY183471A (en) | Formulation for anti-?4?7 antibody | |
MX2021008112A (es) | Formulacion para anticuerpo anti-a4b7. | |
UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
BR112014008552A2 (pt) | r(+)-n-metil-propargilaminoindano | |
MX335944B (es) | Composiciones que comprenden sulfato de salbutamol. | |
MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
BR112014011609A2 (pt) | material de distribuição de fármaco polimérico, método para produção do mesmo, e método para distribuição de uma composição de distribuição de fármaco | |
MA37693A1 (fr) | Composition pharmaceutique ayant une meilleure pulvérulence, agent médicamenteux, procédé de fabrication et application | |
EA201590193A1 (ru) | Препараты лаквинимода без подщелачивающего агента | |
MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
MX2022013566A (es) | Anticuerpo. | |
BR112012017691A2 (pt) | nova composição | |
BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
WO2016195194A3 (fr) | Nouveaux antagonistes de tlr2 | |
WO2018211336A3 (fr) | Forme galénique solide contenant du tosylate de sorafénib | |
IL285073A (en) | Concentrated liquid pharmaceutical preparations of furosemide and methods of administering these preparations | |
MX2017013643A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz. | |
CR20220620A (es) | Composición farmacéutica acuosa de levilimab y su uso |